Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PharmaMar and J&J move cancer drug into phase III
This phase III study compares monotherapy liposomal doxorubicin, a Johnson & Johnson product known as Caelyx in Europe and Doxil in the US, to a combination of Yondelis
This phase III study compares monotherapy liposomal doxorubicin, a Johnson & Johnson product known as Caelyx in Europe and Doxil in the US, to a combination of Yondelis
The overall transaction volume amounts to approximately $590 million including cash, a 10% equity interest in Talecris Biotherapeutics Holdings Corp, retention of selected working capital items, and contingent
A recent study, which was published in the journal Arthritis Research and Therapy, shows that TNF-alpha blocking agents trigger skin conditions in 25% of patients undergoing treatment. TNF-alpha
Although Viagra (sildenafil) didn’t actually lower mothers’ blood pressure, “it did produce some very significant and beneficial effects on pregnancy-induced vascular adaptation and fetal outcome,” according to senior
The study by the Radiation Therapy Oncology Group (RTOG), involving nearly 1,000 patients with locally advanced prostate cancer, is one of the longest and largest studies of its
Astellas’ focus will be on developing breakthrough products in the areas of immunology, infectious disease, dermatology, urology and cardiovascular disease, while continuing to explore unmet needs in other
The five-year award supports the development of advanced techniques using a cell- based, rather than an egg-based, approach to producing influenza vaccines. Under the contract, Sanofi Pasteur will
The FDA’s office of generic drugs has determined the Ranbaxy formulation of nitrofurantoin monohydrate/macrocrystals capsules 100mg to be bioequivalent and have the same therapeutic effect as that of
As an interim step, the company will establish a Level I program of American depositary receipts (ADRs) to enable dollar-denominated trading of its ordinary shares prior to the
Bacterial superantigens are among the most lethal of toxins that can potentially be used as bioweapons. Callisto’s lead monoclonal antibody (Mab) and antagonist peptide are being developed to